Strategic partnerships Position Scholar Rock as a partner for neuromuscular and rare disease programs by offering access to their TGFβ superfamily biology platform and muscle-targeted therapies such as apitegromab, creating opportunities for co-development, collaboration, or milestone-based licensing with mid-to-large pharma seeking novel growth factor–modulating approaches.

SMA advancement Leverage the company’s clinical proof of concept in SMA and upcoming apitegromab development to target specialty clinicians, patient advocacy groups, and payers with value propositions around improved motor function and disease modification, highlighting potential expansion into related motor neuron disorders.

Clinical presentation Explore opportunities to sponsor or participate in key industry conferences and research congresses where Scholar Rock showcases neuromuscular portfolio, enabling timely engagement with KOLs, researchers, and potential collaborators to accelerate awareness and deal-making.

Financial readiness Utilize the company’s substantial funding and mid-point revenue range to pursue strategic partnerships or equity-backed collaborations, offering scalable development pathways and risk-sharing models that align with investors and contractRx strategies.

Technology stack Assess integration opportunities with Scholar Rock’s digital and data platforms (Azure AD, SharePoint Online, Genesis Framework, OpenResty) to support joint programs, data sharing, or digital collaboration tools that streamline joint research, regulatory submissions, and program governance.